Biomarkers & Translational Tools (BTT)

PI-003 - BIOMARKER UTILIZATION IN NEUROLOGICAL DRUG PRODUCTS APPROVED BY FDA (2008-2023): A LANDSCAPE ANALYSIS.

PI-004 - DIGITAL HEALTH BIOMARKERS FOR CHARACTERIZING DEPRESSION SEVERITY TRAJECTORIES DURING ANTIDEPRESSANT TREATMENT.

PI-007 - PROTEOMIC SIGNATURES IN THE CEREBROSPINAL FLUID (CSF) OF INDIVIDUALS WITH PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE (AD): A KEY ROLE FOR ENDOTHELIAL AND ADHESION PROTEINS IN PRECLINICAL AD.

PI-008 - USING BIOMARKERS TO PROVIDE EVIDENCE OF EFFECTIVENESS IN DRUG DEVELOPMENT FOR RARE DISEASES: SURVEY RESULTS FOR APPROVED ENZYME REPLACEMENT THERAPIES.

PII-003 - COMPLIANCE, USABILITY, RELIABILITY, AND CONSTRUCT VALIDITY OF SELF-ADMINISTERED DIGITAL MEASURES DERIVED FROM MDS-UPDRS PARTS 2 AND 3 IN AN OBSERVATIONAL STUDY TO EVALUATE PARKINSON'S DISEASE (PD) PROGRESSION: INTERIM ANALYSIS.

PII-004 - EVALUATING THE UTILITY OF ENDOGENOUS OCT2 AND MATE1/2-K BIOMARKERS FOR EARLY DDI ASSESSMENT IN ONCOLOGY PHASE 1 STUDIES

PII-005 - ITPA ACTIVITY TO PREDICT REMISSION WITH METHOTREXATE IN JUVENILE IDIOPATHIC ARTHRITIS

PII-006 - PHARMACODYNAMIC MODELS AS EARLY PREDICTORS OF WEIGHT LOSS EFFICACY IN EARLY-PHASE CLINICAL RESEARCH

PII-007 - PYRIDOXIC ACID AS ENDOGENOUS BIOMARKER OF RENAL ORGANIC ANION TRANSPORTER ACTIVITY: POPULATION VARIABILITY AND MECHANISTIC MODELING TO PREDICT DRUG-DRUG INTERACTIONS

LB-001 - MODELING AND SIMULATION OF POLYAMINE KINETICS DURING ACUTE KIDNEY INJURY

PT-001 - UTILITY OF A PANEL OF ENDOGENOUS BIOMARKERS TO PREDICT DRUG-DRUG INTERACTIONS AND INTERINDIVIDUAL VARIABILITY INVOLVING ORGANIC ANION TRANSPORTERS 1 AND 3 ACTIVITY.

OAII-002 - EXTREME GRADIENT BOOSTING COMPARED TO TRADITIONAL MODELING FOR PREDICTING PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA

PWII-001 - UTILITY OF A PANEL OF ENDOGENOUS BIOMARKERS TO PREDICT DRUG-DRUG INTERACTIONS AND INTERINDIVIDUAL VARIABILITY INVOLVING ORGANIC ANION TRANSPORTERS 1 AND 3 ACTIVITY.